New York Oncology Hematology PC - Troy

Troy, New York 12180

0 studies enrolling now · 12 studies all time

What they study most

Advanced Pancreatic Neuroendocrine Tumor, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Clear Cell Renal Cell Carcinoma, Extensive Stage Small Cell Lung Carcinoma, Gastrinoma, Glucagonoma, HER2/Neu Positive, Head and Neck Squamous Cell Carcinoma, Hormone Receptor Positive, Insulinoma, Islet Cell Carcinoma

Studies at this site

• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery — Running, not enrolling
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage — Completed
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery — Completed
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery — Completed
• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer — Running, not enrolling
• Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors — Running, not enrolling
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer — Completed
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy — Completed
• Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence — Stopped early
• Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery — Completed
• Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer — Completed